Avacopan or Glucocorticoids for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Rapidly Progressive Glomerulonephritis.

ABSTRACT:

Introduction

The best immunosuppressive regimen to treat severe forms of antineutrophil cytoplasmic autoantibody (ANCA)-associated rapidly progressive glomerulonephritis (RPGN) remains elusive because patients with the lowest estimated glomerular filtration rate (eGFR) have been excluded from most studies, and kidney biopsy has not been a prerequisite for inclusion.

Methods

In a cohort of 70 adult patients with severe ANCA-RPGN (eGFR: 0-30 ml/min per 1.73 m² [mean: 12 ± 8]; anti-myeloperoxidase [MPO] antibodies: 76%, relapsing ANCA-associated vasculitis [AAV]: 6%) where a kidney biopsy was available, we compared kidney outcomes at month 6 and 12 according to induction regimen scheme (avacopan- vs. glucocorticoid [GC]-based).

Results

Fifty patients received

SUBMITTER: Faguer S 

PROVIDER: S-EPMC12639830 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature